© John Wiley & Sons Ltd
All articles accepted from 14 August 2012 are published under the terms of the Creative Commons Attribution License. All articles accepted before this date, were published under a Creative Commons Attribution Non-Commercial License.
Edited By: Qingyi Wei, M.D., Ph.D.
Impact Factor: 2.915
ISI Journal Citation Reports © Ranking: 2015: 107/213 (Oncology)
Online ISSN: 2045-7634
Recently Published Issues
NEW: Read our latest accepted articles!
Meet the Editor
Dr Wei is a highly published and cited author who is based at one of the world’s leading cancer research centres. His previous editorial work includes a role as a Senior Editor on the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
His primary research interest is to explore and develop biomarkers for molecular epidemiologic study for assessing cancer susceptibility with an emphasis on DNA repair and apoptosis. His research is aimed at identifying individuals at high risk of developing cancer. This allows for personalisation in cancer research, with an aim to achieve primary prevention, early diagnosis and targeted therapies. The biomarker assays used in his lab are used in studies of cancers of the lung, head and neck cancer, skin, and breast.
Cancer Medicine'sEditorial Board
Qingyi Wei, MD, PhD
Duke Cancer Institute, Duke University Medical Center,
Brock C. Christensen, PhD
Dartmouth Medical School,
Matthew B. Schabath, PhD
H. Lee Moffitt Cancer Center and Research Institute,
Clinical Cancer Research
Dhyan Chandra, PhD
Roswell Park Cancer Institute,
Buffalo, NY, USA
Zhi-Ming Shao, MD
Shanghai Medical School,
Shanghai, P. R. China
Eric T. Wong, MD
Beth Israel Deaconess Medical Center,
Joseph D. Khoury, MD
The University of Texas M. D. Anderson Cancer Center,
Surya P. Rednam, MD
Texas Children’s Cancer Center,
Sam W. Lee, PhD
Massachusetts General Hospital,
Charlestown, MA, USA
Shanghai Medical School, Fudan University,
Wenge Zhu, PhD
The George Washington University School of Medicine and Health Science,
Washington DC, USA
Journal News from Cancer Medicine
Cancer Medicine is pleased to announce its first Impact Factor of 2.5!
PubMed, MEDLINE and ISI:Cancer Medicine articles are deposited into PubMed Central (PMC) upon publication of an online issue and are therefore searchable on PubMed. In addition, Cancer Medicine has recently been accepted for MEDLINE and ISI indexing, allowing heightened search capabilities for the journal and citation of the journal to contribute to the new Impact Factor.
Submit an Article
We would like to invite you to submit your paper to Cancer Medicine. Reasons to submit:
- High standard, rigorous peer review
- International Editorial Board
- Rapid publication
- Open access and fully compliant with open access mandates
- Authors retain copyright
- Wiley's tradition in publishing excellence
Cancer Medicineis a peer-reviewed, open access, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences, in the areas of, but not limited to, cancer biology, clinical cancer research, and cancer prevention.
Cancer Medicineis a Wiley Open Access journal, one of a new series of peer reviewed titles publishing quality research with speed and efficiency. For further information visit theWiley Open Access website.
Cancer Medicine is supported by Leading Journals and Societies
Cancer Medicine is supported by other journals published by Wiley on behalf of the world's most prestigious cancer societies. The journals listed here support Cancer Medicine and participate in the Manuscript Transfer Program by referring articles of suitable quality and offering authors the option to have their paper, with any peer review reports, automatically transferred to Cancer Medicine.